### **CASE REPORT FORM**

Patient Characteristics	Preoperative Characteristics continued
Case ID* No patient or center identifiers allowed. Age* years Gender* Male Female Height* cm Weight* kg	COVID-19 Status*  No previous diagnosis of COVID-19  Previous diagnosis of COVID-19 Diagnosed >4 weeks  Current diagnosis of COVID-19 Diagnosed within 4 weeks  Unknown COVID-19 status
Preoperative Characteristics	Preoperative blood values
ASA Status*  (ASA: American Society of Anesthesiologists – Physical Status Classification system)  ASA 1 — A normal healthy patient  ASA 2 — A patient with mild systemic disease  ASA 3 — A patient with severe systemic disease  ASA 4 — A patient with severe systemic disease that is a constant threat to life  Comorbidities* None Cardiac disease (Arterial hypertension is NOT considered as cardiac disease)	Hemoglobin* g/L  (Normal range typically 115-180 g/L)  Creatinine* μmol/l  (Normal range typically 50-120 μmol/L)  Albumin g/L  (Normal range typically 35-50 g/L)  Bilirubin* μmol/L  (Normal values typically <17 μmol/L)  CA 19-9 U/ml  (Normal values typically <27 U/ml)  Preoperative therapy*  (Related to the current disease)
Diabetes mellitus Chronic renal failure  Metastatic cancer Cirrhosis Stroke  Asthma COPD (Chronic obstructive Pulmonary Disorder)  Other (Please indicate below)  If other comorbidity, please indicate	(Related to the current disease)  No preoperative therapy  Preoperative chemotherapy  Preoperative radiotherapy  Preoperative chemoradiotherapy  (Chemotherapy and radiotherapy at the same time)  Preoperative sequential chemoradiotherapy (chemotherapy followed by radiotherapy)
If concomitant or previous cancer, please indicate below. (Occurring or existing at the same time as pancreatic cancer or diagnosed previously E.g. Lung, colorectal, endometrial cancer.)	If preoperative chemotherapy, please indicate regime used
If diabetic preoperatively, please, indicate management Diet Controlled Oral antidiabetics Insulin  Pancreatic enzyme supplementation preoperatively (Enzyme supplements containing Pancreatin, a mixture of pancreatic enzymes, lipase, amylase and protease e.g. Creon) Yes No Unknown	Preoperative stent* (ERCP: Endoscopic Retrograde Cholangiopancreatography. PTBD: Percutaneous Transhepatic Biliary Drainage) None ERCP Stent PTBD stent Failed ERCP but successful PTBD stent Unknown

### **Operation Characteristics**

### Approach\*

Open Laparoscopic Robotic Laparoscopic converted to open Robotic converted to laparoscopic Robotic converted to open

If open, incision performed\* Midline Transverse
Rooftop "L" Inverted "L" Other

### Procedure performed\*

Pancreatoduodenectomy – Whipple's

Pancreatoduodenectomy – Pylorus preserving (PPPD)

Distal Pancreatectomy and splenectomy

Distal Pancreatectomy - Spleen Preserving

Pancreatic Duct drainage procedure (e.g. Frey,

Puestow, Beger)

Total Pancreatectomy and splenectomy

Total Pancreatectomy - Spleen preserving

Enucleation

Other pancreatic operation (indicate below)

### If other operation performed, please indicate

\_\_\_\_\_

# Portomesenteric venous resection and reconstruction performed\*

(Any type of portomesenteric resection, including the portal vein and/or the superior mesenteric vein.)

Yes No

# If Portomesenteric venous resection performed, please indicate reconstruction technique

Tangential End-to-end
Autologous or cadaveric graft
Prosthetic graft (biologic or synthetic)

### Arterial resection and reconstruction performed\*

(The term "arterial resection" refers to the superior mesenteric or hepatic artery)

Yes No

### **Operation Characteristics** continued

### **Extended procedure including resection of additional**

organs\* (If yes, please indicate below)

Yes No

If resection was extended to additional organs, please indicate below: (e.g. Colon, adrenal, liver resection)

Operation duration \_\_\_\_\_ minute

#### Texture of Pancreas\*

(As assessed by the surgeon intraoperatively)

Soft/normal Hard/fibrotic Unknown

Size of pancreatic duct\*

<3mm 3-10mm >10mm unknown

### Pancreatic anastomosis\*

None Pancreaticojejunostomy

Pancreaticogastrostomy

# If pancreatic anastomosis performed, indicate technique

Duct to Mucosa Dunking/invagination

# If distal pancreatectomy performed, indicate closure of the pancreatic remnant stump (multiple options)

Hand-sewn closure Stapler closure
Reinforced staple line Seromuscular patch

Separate ligation of pancreatic duct Pancreaticoenteric anastamosis

Falciform ligament patch Fibrin Glue Sealing Surface Active Meshes (e.g. Tachosil) Other

Estimated blood loss intraoperatively \_\_\_\_\_ mL

Intraoperative blood transfusions\* \_\_\_\_\_ Unit

(Please indicate "0" if no blood transfusions)

#### Use of pancreatic stent\*

(i.e. percutaneous surgical drain)

Yes No Unknown

Surgical drain\*

Yes No Unknown

Octreotide administration intra-/postoperatively\*

Yes No

### **Final Pathological Diagnosis** Final histological diagnosis\* Pancreatic ductal adenocarcinoma Ampullary carcinoma Duodenal adenocarcinoma Cholangiocarcinoma Neuroendocrine neoplasia Chronic pancreatitis Benign cystic lesions Intraductal papillary mucinous neoplasm (IPMN) Other If other histological diagnosis, please indicate Tumour size (if applicable) \_\_\_\_\_ mm Lymphovascular invasion (if applicable) Yes No Unknown Perineural invasion (if applicable) Unknown Portal vein (PV) involvement on histology (if PV resection) Yes No Unknown

#### TNM classification AJCC 8<sup>th</sup> edition (cancer) рT Tx T0 Tis T1 T1a T<sub>1</sub>b T<sub>1</sub>c T2 T3 T3a T3b T4 pΝ N0 N1 N3 Nx N2 M Mx M1 M2 Total number of lymph nodes resected: Total number of positive lymph nodes resected:

	<b>1 class</b> inued	ificatio	on AJ(	CC 8th	editi	on (ca	ancer)
<b>Stagi</b> 0	• •	all canc	•	IIB	III	IV	
Histo	logic G	rade (fo	r all ca	ncers)			
Gx	_	G2	G3	G4			
<b>Rese</b> R(		<b>argins (</b> R2	for all o	ancers	)		
If R1	/R2, ma	rgins fo	r pancı	eatodu	ıoden	ectomi	es for
all ca	ncers	Ante	rior sur	face	Post	erior m	argin
SM	1V marg	in S	MA ma	rgin			
Pa	ncreatio	neck/t	ransect	ion ma	rgin		
Proximal duodenal/gastric margin							
Common bile duct margin							
Dis	Distal duodenal margin						
Po	rtal veir	n resect	ion mai	gin	Oth	er	

Postoperative course from operation until				
discharge				
Intensive care unit stay*days				
(If no admission to the intensive care unit, then indicate "0". If				
there was an unplanned readmission, then please indicate the				
total number of ITU unit stay in days.)				
Intermediate care (IMC) or high dependency unit				
(HDU) stay*days				
(If no admission to the IMC/HDU, then indicate "0". If there was				
an unplanned readmission, then please indicate the total number				
of IMC/HDU unit stay in days.)				
Postoperative hospital stay*days				
(i.e the total postoperative hospital stay until hospital discharge				
including ITU/IMC/HDU days)				
Blood transfusions postoperatively units				
(If no blood transfusions administered post-operatively then				
indicate "0")				
Insulin for glycemic control postoperatively*				
Yes No				

**Continued Overleaf** 

Complication types and grades according to the Clavien-Dindo classification until discharge\*

*This field is mandatory grades of complications includes embolism. Gas ISCGF is described below you for further clarifica	s listed ab trointestii w. In case	ove. In c nal: e.g. of comp	ase of other ty ileus, diarrhea lex cases, such	pes of compl Infection: ir as bleeding,	lications, pled acludes woun , leading to n	ise indicate b d infections.	pelow the type The type of p	oes. Note: Puln pancreatic fist	nonary complications
		No	1	2	3a	3b	4a	4b	5
Delayed gastric en									
Pancreation									
Postoperative b	-								
•	/ fistula								
Gastrojejunostor	·								
,	yle leak								
Portal vein Thro	mbosis								
Pulr	monary								
Gastroin	testinal								
(	Cardiac								
U	Irologic								
In	fection								
Neu	ırologic								
CO	VID-19								
(	Other 1								
(	Other 2								
(	Other 3								
If death (grade 5) t	hen ple	ase ind	icate cause	of death:					
If the patient deve	loped a	pancre	atic fistula,	please in	dicate the	ISGPS grad	de		
No fistula A	١	В	С						
If the patient deve	loped d	elayed	gastric emp	tying, ple	ase indicat	e the ISGF	PS grade		
No DGE A	. 1	В	С						
If the patient deve clinical management. G procedures) but manag No bile leakage	Grade B: Bi	ile leaka	ge requiring a	change in pa	itients clinica	l manageme	nt (eg, additi	ional diagnost	
If the patient deve									
impairment. Observation CT scan, angiography, e	embolisati	on or su	rgery. Grade C	: Late / sever	re: Life-threa	ening. CT sco			
surgery. N	io posto	perativ	e bleeding	А	В	С			

# Additional complications from hospital discharge until 90 days postoperatively

Please report all complications up to 90 days postoperatively excluding those already stated above (i.e. those during hospitalization)

### **Complication 1 after hospital discharge**

Comp	licatio	n 1 typ	e			
Comp	licatio	n 1 gra	de:			
1	2	3A	3B	4A	4B	5(Death)

Days from operation to complication 1 \_\_\_\_\_days

### Complication 2 after hospital discharge

Complication 2 type

Comp	iicatic	nı z typ	c			
Comp	licatio	n 2 gra	de:			
1	2	3A	3B	4A	4B	5(Death)

Days from operation to complication 2 days

### **Complication 3 after hospital discharge**

Comp	olicatio	on 3 typ	e			
Comp	olicatio	n 3 gra	de:			
1	2	3A	3B	4A	4B	5(Death)

#### Hospital readmission within 90 days postoperatively

Days from operation to complication 3 days

**(for all cancers)** (Hospital readmission is defined as any type of hospitalization within the same hospital the patient was operated or any other hospital. This applies to all reasons of readmission, including indirectly related to the main pancreatic operation.)

Yes No Unknown

### **Pancreatic Insufficiency**

### Insulin administration at 90 days post-operatively

Yes No Unknown

# Pancreatic enzyme supplementation at 90 days postoperatively

Yes No Unknown
Enzyme supplements containing Pancreatin, a mixture of pancreatic enzymes, lipase, amylase and protease e.g.Creon

### **Adjuvant Chemotherapy**

Patient offered chemotherapy within 90 days postoperatively (for all cancers)

Yes	No	Unknown

If chemotherapy offered, please indicate regime used:

# Patient offered radiotherapy within 90 days postoperatively (for all cancers)

Yes No Unknown

### If radiotherapy offered, please indicate type

External Bean Radiation therapy
Intensity-modulated Radiation therapy (IMRT)
Stereotactic Body Radiation therapy (SBRT)
Image-guided radiation therapy (IGRT)
Volumetric modulated arc therapy (VMAT)
Other type
Unknown

### **Data completion**

### All data until discharge from hospital is complete

(Please check the box if all data is complete until discharge. If not complete by the end of the study period, the case will be excluded from the analysis.)

# All data until 90 days postoperatively follow up are complete

(Please check the box if all data is complete until 90 days postoperatively. If not complete by the end of the study period, the case will be excluded from the analysis)

### **Comments (Optional)**